These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32170579)

  • 1. Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications.
    Bensalem A; Ternant D
    Clin Pharmacokinet; 2020 Jul; 59(7):857-874. PubMed ID: 32170579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.
    Ternant D; Azzopardi N; Raoul W; Bejan-Angoulvant T; Paintaud G
    Clin Pharmacokinet; 2019 Feb; 58(2):169-187. PubMed ID: 29802542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics.
    Gill KL; Machavaram KK; Rose RH; Chetty M
    Clin Pharmacokinet; 2016 Jul; 55(7):789-805. PubMed ID: 26818483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetic variability of therapeutic antibodies].
    Ternant D; Chhun S
    Med Sci (Paris); 2019 Dec; 35(12):1130-1136. PubMed ID: 31903927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors.
    de Vries Schultink AHM; Bol K; Doornbos RP; Murat A; Wasserman E; Dorlo TPC; Schellens JHM; Beijnen JH; Huitema ADR
    Clin Pharmacokinet; 2020 Jul; 59(7):875-884. PubMed ID: 32006223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
    Passot C; Pouw MF; Mulleman D; Bejan-Angoulvant T; Paintaud G; Dreesen E; Ternant D
    Ther Drug Monit; 2017 Aug; 39(4):322-326. PubMed ID: 28703717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.
    Dreesen E; Gils A; Vermeire S
    Curr Drug Targets; 2018; 19(7):757-776. PubMed ID: 26953243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
    Bruin G; Loesche C; Nyirady J; Sander O
    J Clin Pharmacol; 2017 Jul; 57(7):876-885. PubMed ID: 28273356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
    Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
    J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed Dosing of Monoclonal Antibodies in Oncology.
    Hendrikx JJMA; Haanen JBAG; Voest EE; Schellens JHM; Huitema ADR; Beijnen JH
    Oncologist; 2017 Oct; 22(10):1212-1221. PubMed ID: 28754722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial.
    Ng CM; Bruno R; Combs D; Davies B
    J Clin Pharmacol; 2005 Jul; 45(7):792-801. PubMed ID: 15951469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.
    Bajaj G; Suryawanshi S; Roy A; Gupta M
    Br J Clin Pharmacol; 2019 Sep; 85(9):2045-2058. PubMed ID: 31140642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.
    Edlund H; Melin J; Parra-Guillen ZP; Kloft C
    Clin Pharmacokinet; 2015 Jan; 54(1):35-80. PubMed ID: 25516414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.